Explore

Trendline Trendline
FDA Approval of Regeneron's Otarmeni Marks Progress in Gene Therapies for Hearing Loss

FDA Approval of Regeneron's Otarmeni Marks Progress in Gene Therapies for Hearing Loss

FDA Approval of Regeneron's Otarmeni Marks Progress in Gene Therapies for Hearing Loss
Trendline Trendline
Harbour BioMed Unveils Promising Preclinical Data for AI-Enabled Obesity Drug LET003

Harbour BioMed Unveils Promising Preclinical Data for AI-Enabled Obesity Drug LET003

Harbour BioMed Unveils Promising Preclinical Data for AI-Enabled Obesity Drug LET003
Trendline Trendline
ImmunityBio Secures U.S. Agreement for Tokyo Strain of BCG to Address Bladder Cancer

ImmunityBio Secures U.S. Agreement for Tokyo Strain of BCG to Address Bladder Cancer

ImmunityBio Secures U.S. Agreement for Tokyo Strain of BCG to Address Bladder Cancer
Rapid Read Rapid Read
ImmunityBio Secures U.S. Rights for Tokyo Strain of BCG to Address Shortage

ImmunityBio Secures U.S. Rights for Tokyo Strain of BCG to Address Shortage

ImmunityBio, Inc. has signed an exclusive U.S. Development and Supply Agreement with Japan BCG Laboratory for the Tokyo strain of BCG (Tokyo-172 BCG). This agreement aims to address the longstanding BCG shortage in the United States by providing a second potential source of BCG. The Tokyo strain has shown non-inferior efficacy compared to TICE BCG in a Phase III trial for high-grade non-muscle invasive bladder cancer. ImmunityBio plans to engage with the FDA to pursue approval for this strain, which has been used in Japan for nearly 30 years.
Trendline Trendline
Harbour BioMed Unveils Promising Preclinical Data for AI-Enabled Drug LET003 Targeting Obesity

Harbour BioMed Unveils Promising Preclinical Data for AI-Enabled Drug LET003 Targeting Obesity

Harbour BioMed Unveils Promising Preclinical Data for AI-Enabled Drug LET003 Targeting Obesity
Trendline Trendline
Amylyx Pharmaceuticals Publishes Phase 2 Trial Data for AMX0035 in Wolfram Syndrome

Amylyx Pharmaceuticals Publishes Phase 2 Trial Data for AMX0035 in Wolfram Syndrome

Amylyx Pharmaceuticals Publishes Phase 2 Trial Data for AMX0035 in Wolfram Syndrome
Trendline Trendline
Harbour BioMed's AI-Enabled Drug Candidate LET003 Shows Promising Preclinical Results

Harbour BioMed's AI-Enabled Drug Candidate LET003 Shows Promising Preclinical Results

Harbour BioMed's AI-Enabled Drug Candidate LET003 Shows Promising Preclinical Results
Trendline Trendline
GenSight Biologics to Discuss Strategic Priorities at General Meeting

GenSight Biologics to Discuss Strategic Priorities at General Meeting

GenSight Biologics to Discuss Strategic Priorities at General Meeting
Trendline Trendline
FDA Alignment and AI Integration Crucial for Rare Disease Treatment Advancements

FDA Alignment and AI Integration Crucial for Rare Disease Treatment Advancements

FDA Alignment and AI Integration Crucial for Rare Disease Treatment Advancements
Trendline Trendline
FDA Approves AstraZeneca's Baxfendy, a New Class of Hypertension Drug

FDA Approves AstraZeneca's Baxfendy, a New Class of Hypertension Drug

FDA Approves AstraZeneca's Baxfendy, a New Class of Hypertension Drug
Trendline Trendline
CREATE Secures $122 Million to Advance CAR T Therapy in Cancer and Autoimmune Diseases

CREATE Secures $122 Million to Advance CAR T Therapy in Cancer and Autoimmune Diseases

CREATE Secures $122 Million to Advance CAR T Therapy in Cancer and Autoimmune Diseases
Trendline Trendline
Biogen's Alzheimer's Results Support Tau Theory, Boosting Denali's Prospects

Biogen's Alzheimer's Results Support Tau Theory, Boosting Denali's Prospects

Biogen's Alzheimer's Results Support Tau Theory, Boosting Denali's Prospects